Business
Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance
CAMBRIDGE, Mass., October 16, 2025--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced the issuance of its 23rd patent from the United States Patent and Trademark Office (USPTO) for novel compounds within its neuroplastogenic patent estate, further expanding its intellectual property assets for the potential treatment of mental heal
About this update from Enveric Biosciences, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/88886932909bbe0daf32643ce861d3b0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CQsOqPSJddOKWRN9Ylu.YQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/88886932909bbe0daf32643ce861d3b0","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/V4HF1HWsKkXEc20hmpN6tA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/88886932909bbe0daf32643ce861d3b0","width":1024,"height":512}},"lazy":false},{"type":"text","content":"New patent marks Enveric’s 23rd issued U.S. patent for novel neuroplastogen molecules, increasing Enveric’s intellectual property footprint and supporting the potential for pipeline expansion","length":191,"tagName":"p","attribs":{}},{"type":"text","content":"CAMBRIDGE, Mass., October 16, 2025--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced the issuance of its 23rd patent from the United States Patent and Trademark Office (USPTO) for novel compounds within its neuroplastogenic patent estate, further expanding its intellectual property assets for the potential treatment of mental health disorders.","length":550,"tagName":"p"},{"type":"text","content":"The patent, U.S. Patent No. 12,428,408, titled, "Fused Heterocyclic Mescaline Derivatives," covers a unique series of compounds, which are designed to target key serotonin receptors and drive neuroplasticity.","length":218,"tagName":"p"},{"type":"text","content":""The issuance of this 23rd U.S. patent in Enveric’s neuroplastogenic patent estate demonstrates Enveric’s continued momentum and commitment to the development of a strong intellectual property portfolio and deep pipeline of next-generation molecules for potential development for the treatment of neuropsychiatric conditions," said Joseph Tucker, Ph.D., Director and CEO of Enveric.","length":392,"tagName":"p"},{"type":"text","content":"About Enveric Biosciences","length":25...